Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Current pharmaceutical design, 2013, Vol.19 (27), p.4888-4892
2013
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
Cardiac stem cell regeneration in metabolic syndrome
Ist Teil von
  • Current pharmaceutical design, 2013, Vol.19 (27), p.4888-4892
Ort / Verlag
United Arab Emirates
Erscheinungsjahr
2013
Quelle
MEDLINE
Beschreibungen/Notizen
  • The metabolic syndrome (MetS) is a constellation of multiple metabolic risk factors including obesity, glucose intolerance, insulin resistance, dyslipidemia and hypertension. Individuals with MetS are found to be afflicted with an increased risk of type 2 diabetes mellitus and overall cardiovascular diseases. One of the common comorbidities of MetS is the impairment of heart function en route to loss of cardiomyocytes and ultimately heart failure. Although it is accepted that cardiomyocytes are terminally differentiated, recent evidence has challenged this concept to indicate the ability of cardiomyocytes to regenerate from progenitor cells of the heart and other organs. Moreover, it has been suggested that pathological conditions such as MetS may play a role in the regulation of cardiomyocyte regeneration. This mini-review will discuss the role of MetS in the regulatory machineries of cardiomyocyte regeneration.
Sprache
Englisch
Identifikatoren
ISSN: 1381-6128
eISSN: 1873-4286
DOI: 10.2174/1381612811319270011
Titel-ID: cdi_pubmed_primary_23323616

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX